机构:[1]Guangzhou Institute of Clinical Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong Province, China.[2]Department of Clinical Nutrition, Chengdu 7 th People's Hospital, Chengdu Medical College, Chengdu, Sichuan Province, China.[3]Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong Province, China.[4]Department of Neurosurgery, CHA University, CHA Bundang Medical Center, Seongnam, Korea.[5]National Institute of Stem Cell Clinical Research, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.广东省中医院
Spinal cord injury (SCI) is a result of a devastating injury to the central nervous system. Currently, there is no effective treatment available for these patients. The possible use of mesenchymal stem cell (MSC)-based treatment for SCI has been the focus of extensive investigations and is increasingly moving from the bench to bedside. Both experimental observations and clinical studies have shown the safety and efficacy of MSCs in managing SCI. However, the exact mechanism by which MSCs contribute to the repair of the injured spinal cord remains to be elucidated. In this review, we aim to summarize current research findings about the role of MSCs in improving complex pathology after SCI. MSCs exert a multimodal repair mechanism targeting multiple events in the secondary injury cascade. Our recent results showing the perineurium-like differentiation of surviving MSCs in the injured spinal cord may further the understanding of the fate of transplanted MSCs. These findings provide fundamental support for the clinical use of MSCs in SCI patients. Under experimental conditions, combining novel physical, chemical, and biological approaches led to significant improvements in the therapeutic efficacy of MSCs. These findings hold promise for the future of cell-based clinical treatment of SCI.
基金:
This research was supported by grants
from the Chinese National Natural Science Foundation (Grant
No. 31900975 to Y. H. Ma); the Natural Science Foundation of
Guangdong Province (Grant Nos. 2018A030310110 and 2020-
A1515011537 to Y. H. Ma); the Start-up Fund Projects of Guangzhou First People’s Hospital (Grant No. KYQD20210017 to Y. H.
Ma) and the Startup Grant of Guangdong Hospital of Chinese
Medicine (Grant No.2022KT1032) to Xiang Zeng.
第一作者机构:[1]Guangzhou Institute of Clinical Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong Province, China.
通讯作者:
通讯机构:[5]National Institute of Stem Cell Clinical Research, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China.[*1]National Institute of Stem Cell Clinical Research, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, #55, Nei Huan Xi Road, Guangzhou Higher Education Mega Center, Guangzhou, Guangdong Province 510006, China
推荐引用方式(GB/T 7714):
Ma Yuan-Huan,Liang Qing-Yue,Ding Ying,et al.Multimodal Repair of Spinal Cord Injury With Mesenchymal Stem Cells[J].NEUROSPINE.2022,19(3):616-629.doi:10.14245/ns.2244272.136.
APA:
Ma Yuan-Huan,Liang Qing-Yue,Ding Ying,Han Inbo&Zeng Xiang.(2022).Multimodal Repair of Spinal Cord Injury With Mesenchymal Stem Cells.NEUROSPINE,19,(3)
MLA:
Ma Yuan-Huan,et al."Multimodal Repair of Spinal Cord Injury With Mesenchymal Stem Cells".NEUROSPINE 19..3(2022):616-629